MedTrace Logo

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

NCT04855721 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2022-12-13

No results posted yet for this study

Summary

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)

Conditions

Interventions

DRUG

AUR101

Oral ROR-gamma inverse agonist

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Aurigene Discovery Technologies Limited

    lead INDUSTRY

Principal Investigators

  • Divyesh Mandavia, MD · Aurigene Discovery Technologies Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2022-11-30
Completion
2022-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855721 on ClinicalTrials.gov